Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af den kliniske effekt og sikkerheden af PRX-115 administreret intravenøst i forskellige doseringsregimer, med og uden methotrexat, versus placebo hos voksne patienter med gigt (RELEASE) (RELEASE)

28. september 2026 opdateret af: Protalix

Et multicenter, randomiseret, dobbeltblindt, placebokontrolleret, fase 2-studie, der vurderer effektiviteten, sikkerheden og valget af doseringsregime for flere intravenøse infusioner af PRX-115 med og uden metotrexat versus placebo hos voksne patienter med gigt (RELEASE)

This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.

Studieoversigt

Detaljeret beskrivelse

This study will evaluate the efficacy, safety, tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PRX-115 (a recombinant pegylated Uricase) in adult patients with gout. Participants will receive PRX-115 by intravenous (IV) infusions according to different treatment schedules, with and without the immunomodulator methotrexate (MTX).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

150

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Head of Clinical Development
  • Telefonnummer: +972-4-902-8100
  • E-mail: info@protalix.com

Studiesteder

    • Arizona
      • Glendale, Arizona, Forenede Stater, 85306
        • Rekruttering
        • Rezen Clinical Trials
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72205
        • Rekruttering
        • Applied Research Center of Arkansas
    • California
      • Anaheim, California, Forenede Stater, 92805
        • Rekruttering
        • Advanced Research Center, Inc
      • El Cajon, California, Forenede Stater, 91910
        • Rekruttering
        • Triwest Research Associates Llc
      • La Palma, California, Forenede Stater, 90623
        • Rekruttering
        • Imax Clinical Trials, LLC
      • Long Beach, California, Forenede Stater, 90806
        • Rekruttering
        • Kinetic Clinical Research
    • Florida
      • Clearwater, Florida, Forenede Stater, 33765
        • Rekruttering
        • Clinical Research of West Florida, Inc.
      • DeLand, Florida, Forenede Stater, 32720
        • Rekruttering
        • Accel Research Sites - Deland Clinical Research Unit
      • Doral, Florida, Forenede Stater, 33125
        • Rekruttering
        • ICR Sites East
      • Hialeah, Florida, Forenede Stater, 33010
        • Rekruttering
        • Qway Research
      • Miami, Florida, Forenede Stater, 33155
        • Rekruttering
        • Bioclinical Research Alliance, Inc
      • Miami, Florida, Forenede Stater, 33169
        • Rekruttering
        • D&H National Research Centers (North Miami)
      • Miami, Florida, Forenede Stater, 33173
        • Rekruttering
        • Well Pharma Medical Research Group
      • Orlando, Florida, Forenede Stater, 32832
        • Rekruttering
        • Conquest Research - Lake Nona
      • Orlando, Florida, Forenede Stater, 32897
        • Rekruttering
        • Combined Research Orlando Phase I-IV
      • Palmetto Bay, Florida, Forenede Stater, 33176
        • Rekruttering
        • New Horizons Research
      • Tampa, Florida, Forenede Stater, 33606
        • Rekruttering
        • Clinical Research of West Florida, Inc.
    • Georgia
      • Columbus, Georgia, Forenede Stater, 31904
        • Rekruttering
        • Centricity Research - Columbus Georgia Multispecialty
    • Michigan
      • Dearborn, Michigan, Forenede Stater, 48126
        • Rekruttering
        • Revival Research Institute, LLC
      • Farmington Hills, Michigan, Forenede Stater, 48334
        • Rekruttering
        • Quest Research Institute
      • Sterling Heights, Michigan, Forenede Stater, 48313
        • Rekruttering
        • Revive Research Institute, Inc
    • Pennsylvania
      • Duncansville, Pennsylvania, Forenede Stater, 16635
        • Rekruttering
        • Altoona Center for Clinical Research
    • Texas
      • Houston, Texas, Forenede Stater, 77099
        • Rekruttering
        • Pioneer Research Solutions Inc
      • Sugar Land, Texas, Forenede Stater, 77479
        • Rekruttering
        • Mt. Olympus Medical Research, LLC - Sugar Land
      • Waco, Texas, Forenede Stater, 76710
        • Rekruttering
        • Velocity Clinical Research
    • Virginia
      • Suffolk, Virginia, Forenede Stater, 23435
        • Rekruttering
        • Velocity Clinical Research
      • Tbilisi, Georgien, 0102
        • Rekruttering
        • Aleksandre Aladashvili Clinic LLC, Georgia
      • Tbilisi, Georgien, 0159
        • Rekruttering
        • Tbilisi Heart and Vascular Clinic Ltd , Georgia
      • Tbilisi, Georgien, 0160
        • Rekruttering
        • Mediclub Georgia
      • Tbilisi, Georgien, 0160
        • Rekruttering
        • Tbilisi Institute of Medicine, Georgia
      • Tbilisi, Georgien, 0172
        • Rekruttering
        • Georgian-Dutch Hospital, Georgia
      • Tbilisi, Georgien, 0180
        • Rekruttering
        • LTD First Medical Center, Georgia
      • Afula, Israel, 1834111
        • Rekruttering
        • HaEmek MC, Israel
      • Ashkelon, Israel, 7830604
        • Rekruttering
        • Barzilai MC, Israel
      • Kfar Saba, Israel, 4438164
        • Rekruttering
        • Meir MC, Israel

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Males or females ≥18 years of age.
  2. Weight within the range of 50.0 - 150.0 kg.
  3. Gout patients who failed to normalize sUA (<7 mg/dL) with or without xanthine oxidase inhibitors or uricosuric agent or have contraindications to these drugs.
  4. Willing to discontinue any oral ULT
  5. Females who are sterile, postmenopausal, or non-pregnant and using birth control methods.

Exclusion Criteria:

  1. Any condition known to have arthritis as a clinical manifestation.
  2. Positive testing for HBV,HCV, or HIV.
  3. The patient is a pregnant or lactating female or plans to become pregnant during the study period.
  4. Known allergy or sensitivity to the injected proteins, including pegylated products.
  5. Prior exposure to any experimental or marketed uricase.
  6. Patient treated with a medication known to have an influence on urate metabolism or clearance such as ULTs.
  7. History of anaphylaxis, severe allergic reactions, or severe atopy.
  8. G6PD deficiency or known catalase deficiency.
  9. History of significant hematologic or autoimmune disorders within 5 years of Screening and/or patient is immunocompromised or treated with immunosuppressive medications.
  10. Non-compensated CHF or hospitalization for CHF (Stage 3-4 NYHA Functional Class) within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled BP (>160/100 mmHg) at screening and prior to randomization at Week -4 (Visit 1).
  11. Current liver disease, as determined by ALT or AST levels above upper limit of normal at Screening Visit.
  12. Chronic liver disease.
  13. Hemoglobin <11 g/dL, neutrophil count <1500 /µl, or platelet count <100,000 /µl.
  14. Known severe pulmonary fibrosis, bronchiectasis or interstitial pneumonitis.
  15. eGFR ≤ 40 mL/min/1.73m2 tested at Screening Visit. Kidney transplant or requires dialysis.
  16. Known intolerance and/or known contraindication to MTX treatment or MTX treatment considered inappropriate
  17. Has uncontrolled type 2 diabetes at Screening with HbA1c ≥8.5%. Patients with type 1 diabetes will be excluded.
  18. Has known latent autoimmune diabetes of adult.
  19. Immunocompromised state, regardless of etiology.
  20. History or treatment of malignancy in the last 5 years, excluding localized, nonmelanoma skin cancers (e.g. basal or squamous cell)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: E4W with placebo-MTX

IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with placebo-MTX

intravenous (IV) infusion

Oral Placebo-MTX weekly

Eksperimentel: E4W with MTX

IV infusion of PRX-115 every 4 weeks (E4W) for a total of 6 doses with MTX

intravenous (IV) infusion

Oral MTX 15 mg weekly

Eksperimentel: E6W with MTX

IV infusion of PRX-115 every 6 weeks (E6W) for a total of 4 doses with MTX

intravenous (IV) infusion

Oral MTX 15 mg weekly

Eksperimentel: E8W with MTX

IV infusion of PRX-115 every 8 weeks (E8W) for a total of 3 doses with MTX

intravenous (IV) infusion

Oral MTX 15 mg weekly

Placebo komparator: placebo E4W

infusion of PRX-115 placebo every 4 weeks (E4W) for a total of 6 doses with placebo-MTX

Oral Placebo-MTX weekly

intravenous (IV) infusion

Placebo komparator: placebo E6W

IV infusion of PRX-115 placebo every 6 weeks (E6W) for a total of 4 doses with placebo-MTX

Oral Placebo-MTX weekly

intravenous (IV) infusion

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Tidsramme: 6 months of treatment

Proportion of patients who achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 6

6 months of treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) at different time points
Tidsramme: 3 to 6 months of treatment

Proportion of patients that achieve a reduction in sUA to <6.0 mg/dL for at least 80% of the time during Month 3 or 4, 5 and 6.

3 to 6 months of treatment
Treatment-emergent adverse events (TEAEs)
Tidsramme: From enrollment to 8 months of study

Occurrence and severity of treatment-emergent adverse events (TEAEs)

From enrollment to 8 months of study

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. december 2025

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. juni 2028

Datoer for studieregistrering

Først indsendt

3. december 2025

Først indsendt, der opfyldte QC-kriterier

3. december 2025

Først opslået (Faktiske)

12. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

28. september 2026

Sidst verificeret

1. september 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner